ReviewHematology/oncology clinics of North America2014
Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.
Review in Hematology/oncology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis.Blood advances · 2022Pooled it
- Sickle cell disease is associated with iron mediated hypercoagulability.Journal of thrombosis and thrombolysis · 2015Trial
- Cytokine and chemokine signatures of steady-state sickle cell disease in African children: a cross-sectional study.BMC immunology · 2026Article
- The Natural Coagulation Inhibitors, Inflammation, and Thrombotic Risk in Sickle Cell Patients in Cameroon: An Analytical Cross-Sectional Study.Advances in hematology · 2026Article
- A Comparative Analysis of Hydroxyurea Treatment on Coagulation Profile Among Sickle Cell Anaemia Children in Lagos, Nigeria.Advances in hematology · 2024Article
- The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications.Antioxidants (Basel, Switzerland) · 2021Review
- A case of Sβ+ sickle cell disease diagnosed in adulthood following acute stroke: it's 2021, are we there yet?Journal of community hospital internal medicine perspectives · 2021Article
- Drug Therapies for the Management of Sickle Cell Disease.F1000Research · 2020Review
- The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.Frontiers in immunology · 2020Review
- Pathophysiology of Sickle Cell Disease.Annual review of pathology · 2019Review
- Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.Hematology. American Society of Hematology. Education Program · 2018Review
- Review
- The Platelet Count and its Implications in Sickle Cell Disease Patients Admitted for Intensive Care.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2018Article
- Protein Z and Endothelin-1 genetic polymorphisms in pediatric Egyptian sickle cell disease patients.Journal of clinical laboratory analysis · 2018Article
- Advances in new drug therapies for the management of sickle cell disease.Expert opinion on orphan drugs · 2018Article
- Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.Journal of thrombosis and thrombolysis · 2017Article
- Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.Journal of thrombosis and thrombolysis · 2017Article
- Sickle cell disease: an inherited thrombophilia.Hematology. American Society of Hematology. Education Program · 2016Review
- Lectin-like oxidized low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy.Blood cells, molecules & diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.